# Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

> **NCT00042341** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 60 (—)

## Conditions studied

- Leukemia, Lymphoblastic, Acute, Pediatric

## Interventions

- **DRUG:** clofarabine (IV formulation)

## Key facts

- **NCT ID:** NCT00042341
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 60 (—)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042341, "Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00042341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*